piperaquine has been researched along with imatinib mesylate in 1 studies
| Studies (piperaquine) | Trials (piperaquine) | Recent Studies (post-2010) (piperaquine) | Studies (imatinib mesylate) | Trials (imatinib mesylate) | Recent Studies (post-2010) (imatinib mesylate) |
|---|---|---|---|---|---|
| 638 | 227 | 497 | 11,477 | 960 | 5,773 |
| Protein | Taxonomy | piperaquine (IC50) | imatinib mesylate (IC50) |
|---|---|---|---|
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | 0.31 | |
| Mast/stem cell growth factor receptor Kit | Homo sapiens (human) | 0.1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chien, HD; Kesely, KR; Low, PS; Noomuna, P; Pantaleo, A; Putt, KS; Tuan, TA; Turrini, FM | 1 |
1 trial(s) available for piperaquine and imatinib mesylate
| Article | Year |
|---|---|
Imatinib augments standard malaria combination therapy without added toxicity.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Drug Therapy, Combination; Fever; Humans; Imatinib Mesylate; Malaria, Falciparum; Middle Aged; Quinolines; Treatment Outcome; Vietnam; Young Adult | 2021 |